Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis

Ginny Secor, Emory University
W. Evan Secor, Emory University School of Medicine
Claire-Anne Gutekunst, Emory University
Melissa A. Brown, Emory University

Journal Title: Journal of Experimental Medicine
Volume: Volume 191, Number 5
Publisher: Rockefeller University Press | 2000-03-06, Pages 813-821
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1084/jem.191.5.813
Permanent URL: https://pid.emory.edu/ark:/25593/rjjsp

Final published version: http://dx.doi.org/10.1084/jem.191.5.813

Copyright information:
© 2000 government

Accessed October 25, 2019 5:57 PM EDT
Mast Cells Are Essential for Early Onset and Severe Disease in a Murine Model of Multiple Sclerosis

By Virginia H. Secor,* W. Evan Secor,† Claire-Anne Gutekunst,§ and Melissa A. Brown‡

From the *Graduate Program in Immunology and Molecular Pathogenesis, the †Department of Pathology and Graduate Program in Genetics and Molecular Biology, and the ‡Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322; and the Immunology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341

Abstract

In addition to their well characterized role in allergic inflammation, recent data confirm that mast cells play a more extensive role in a variety of immune responses. However, their contribution to autoimmune and neurologic disease processes has not been investigated. Experimental allergic encephalomyelitis (EAE) and its human disease counterpart, multiple sclerosis, are considered to be CD4+ T cell–mediated autoimmune diseases affecting the central nervous system. Several lines of indirect evidence suggest that mast cells could also play a role in the pathogenesis of both the human and murine disease. Using a myelin oligodendrocyte glycoprotein (MOG)-induced model of acute EAE, we show that mast cell–deficient W/Wv mice exhibit significantly reduced disease incidence, delayed disease onset, and decreased mean clinical scores when compared with their wild-type congenic littermates. No differences were observed in MOG-specific T and B cell responses between the two groups, indicating that a global T or B cell defect is not present in W/Wv animals. Reconstitution of the mast cell population in W/Wv mice restores induction of early and severe disease to wild-type levels, suggesting that mast cells are critical for the full manifestation of disease. These data provide a new mechanism for immune destruction in EAE and indicate that mast cells play a broader role in neurologic inflammation.

Key words: autoimmunity • demyelinating diseases • experimental allergic encephalomyelitis • inflammation • myelin-associated glycoprotein

Introduction

Experimental allergic encephalomyelitis (EAE),1 the prototypical rodent model of human multiple sclerosis (MS), is an autoimmune disease characterized by inflammation in the central nervous system (CNS) (1–3). Like the human disease, EAE is associated with an early breach of the blood–brain barrier, focal perivascular mononuclear cell infiltrates, and demyelination leading to paralysis of the extremities (1). The adoptive transfer of myelin-specific CD4+ T cells to naive animals passively confers EAE, demonstrating that this cell type is critical in the disease process. However, it is unclear whether these T cells directly damage the myelin sheath or if they activate other cells for this function. The underlying cause of increased vascular permeability that facilitates the entry of T cells into the CNS is also unknown. In this study, we asked if mast cells could influence the T cell response and subsequent EAE disease course. Mast cells, best known for their role in allergic inflammation, are distributed in a variety of anatomical sites, including the CNS, where they are often found adjacent to blood vessels and nerves (4–7). In addition, mast cells are an important source of several mediators, including proteases and vasoactive amines such as histamine. Mast cells also produce cytokines that have been implicated in either EAE disease pathology or protection from disease, such as TNF-α and IL-4, respectively (8–12).
The idea that mast cells contribute to the pathogenesis of MS is not a new concept. Over 100 years ago, mast cells were observed in the CNS plaques of MS patients (13). Subsequent studies reported a correlation between the number and/or distribution of mast cells and MS or EAE pathology (14–16). Sites of inflammatory demyelination are also sites of mast cell accumulation in the brain and spinal cord, and the percentage of degranulated mast cells in the CNS correlates with the clinical onset of disease symptoms in acute EAE (17). Furthermore, levels of tryptase, a mast cell-specific proteolytic enzyme, are elevated in the cerebrospinal fluid in the human disease (18). Mast cell–derived proteases are capable of degrading myelin (19–21), and myelin can directly stimulate mast cell degranulation in vitro (20). Finally, treatment with mast cell–stabilizing drugs or with pharmacologic antagonists of mast cell mediators such as serotonin and histamine was shown to reduce disease severity in human MS and in EAE (22–24). Despite this wealth of correlative data, a direct role for mast cells in the pathogenesis of neurologic disorders such as MS has not been definitively established.

Materials and Methods

Animals. WBB6/F1-Kit+/Kitv- (W/Wv) female mice (8–12 wk old) and their female congenic littermates, WBB6/F1-Kit+/- (F1+/+), were obtained from The Jackson Laboratory. Both of these groups result from the cross of WBB6/F1-Kit+/- x C57BL/6-Kitv- mice. Animal care was provided according to protocols approved by the Institutional Animal Care and Use Committee of Emory University.

EAE Disease Induction and Clinical Scoring. EAE induction was performed according to the protocol of Mendel et al. (25). In brief, 300 µg of myelin oligodendrocyte glycoprotein (MOG)35–55 peptide, MEVGWYRSPFSRVTLYARNGK (Microchemical Facility, Emory University) was dissolved in 100 µl PBS and emulsified in an equal volume of CFA (Difco Labs., Inc.) containing 5 mg/ml of Mycobacterium tuberculosis H37 RA (Difco Labs., Inc.). The emulsion (200 µl) was injected subcutaneously into the flank on days 0 and 7. Pertussis toxin, 500 ng in 500 µl PBS (List Biological Labs.), was administered intravenously into each tail vein on days 0 and 2. Mice were scored daily according to the following clinical scoring system: 0, no clinical disease; 1, tail flaccidity; 2, hind limb weakness; 3, hind limb paralysis; 4, forelimb paralysis or loss of ability to right from supine; 5, death.

Bone marrow–derived mast cell differentiation and reconstitution. Bone marrow was harvested from both femurs of 6–8-wk-old wild-type F1+/+ female mice and cultured in complete RPMI media (15% heat-inactivated FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, and 50 µM 2-β-ME) containing 25% WEHI-3B supernatant as an IL-3 source (26). In contrast to some previously described methods for culturing bone marrow–derived mast cells (BMMCs) (reference 27–29), recombinant murine stem cell factor (12.5 ng/ml; R & D Systems, Inc.) was also added to the culture during the first 2 wk as described (30, 31). This addition consistently increased the viability of the cultured cells. BMMCs were used after a minimum of 4 wk in culture at >96% purity, as determined by flow cytometric analysis. At time of reconstitution, BMMCs (5 × 10⁶ in 300 µl) were injected intravenously into groups of five to seven W/Wv mice. Mice were housed for 10 wk before being subjected to EAE disease induction along with age-matched W/Wv and F1+/+ controls.

Preparation of tissue for histologic examination. After animals were killed, brains, spinal columns, and other organs were removed and preserved in 10% neutral buffered formalin. Tissues were embedded in paraffin, sectioned (5 µm), and stained with hematoxylin and eosin or Giemsa.

Flow cytometry. BMMCs (10⁶ cells in 100 µl) were blocked with antibodies to the Fcγ receptors CD16 and CD32 (PharMingen). Cells were incubated with murine IgE (PharMingen) and then surface stained with directly conjugated mAbs to murine IgE (rat anti–mouse–FITC; PharMingen) and c-kit (c-kit–PE; PharMingen). Flow cytometric analyses for BMMCs purity were carried out with the appropriate isotype controls. Cells double positive for c-kit and FceR1 were considered mast cells.

Determination of anti-MOG Ab titer and level. Antibody level analyses were performed by specific ELISA to detect anti-MOG activity. MOG (0.25 µg/well in 0.1 M NaHCO₃, pH 9.6) was adsorbed onto flat-bottomed microtiter plates overnight at 4°C. After a blocking step of PBS/0.3% Tween 20/5% nonfat dry milk, plates were incubated with 1:100 dilutions of mouse sera in PBS/0.3% Tween 20. Anti-MOG antibodies bound to the MOG-coated plate were detected using peroxidase-conjugated, affinity-purified IgG fractions of isotype-specific goat anti–mouse IgG, IgG1, IgG2a, IgG2b, or IgG3 (PharMingen) diluted 1:10,000 in PBS/0.3% Tween 20. Anti-MOG antibodies bound to the MOG-activated plate were then surface stained with directly conjugated, PE-adsorbed onto flat-bottomed microtiter plates overnight at 4°C. After a blocking step of PBS/0.3% Tween 20/5% nonfat dry milk, plates were incubated with 1:100 dilutions of mouse sera in PBS/0.3% Tween 20. Anti-MOG antibodies bound to the MOG-coated plate were detected using peroxidase-conjugated, affinity-purified IgG fractions of isotype-specific goat anti–mouse IgG, IgG1, IgG2a, IgG2b, or IgG3 (PharMingen) diluted 1:10,000 in PBS/0.3% Tween 20. Assays were developed with 3,3',5',5'-tetramethylbenzidine peroxidase substrate (KPL), stopped with H₂PO₄ (1:20 dilution), and read at a wavelength of 450 nm on a microplate reader.

Statistical Analyses. Statistical analyses were performed using GraphPad Prism (Software for Science). Group mean clinical scores were analyzed by paired t test for comparison of two groups. Repeated measures of analysis of variance (ANOVA), followed by the Bonferroni post-test, were used for comparison of the mean clinical scores of the three groups in the reconstitution experiments. Comparison of group incidence (number of animals with disease/n) was analyzed by Fisher’s exact test. Survival curves (animals positive for disease) were plotted according to the method of Kaplan-Meier, and significance was calculated by the log-rank test. Mean high scores were compared by student’s t test or ANOVA with Bonferroni post-test for comparison of two or three groups, respectively.

Results

W/Wv Mice Show a Delay in Time of Disease Onset and a Reduction in Disease Severity. To directly evaluate the in vivo role of mast cells in acute EAE, mast cell–deficient WBB6/F1-Kit+/Kitv- (W/Wv) mice and their congenic wild-type WBB6/F1-Kit+/Kit+ (F1+/+) littermates (H-2b) were immunized with the encephalitogenic MOG35–55 peptide. MOG can induce typical EAE disease in C57BL/6 mice and other H-2b strains (25). MOG, which comprises only ~0.05% of myelin proteins, elicits a major antibody response that has been correlated with disease severity and demyelination in both human disease and animal models of MS (32–34). In three independent experiments, W/Wv mice developed significantly less severe disease than wild-type mice, as indicated by lower daily mean clinical scores (P < 0.0001; Fig. 1 A). In addition, mast cell–deficient an-
Animals also demonstrated a delayed onset and lower incidence of disease when compared with their wild-type counterparts (P \(<\) 0.0003; Fig. 1 B). Sham-immunized wild-type (n = 3) and mast cell–deficient animals (n = 4) that received pertussis toxin and adjuvant alone showed no clinical signs of disease (data not shown). The cumulative analyses of disease parameters are presented in Table I.

**Inflammatory Infiltrates Are Present in the CNS of Diseased Animals.** In addition to the clinical changes observed, animals were also examined for histologic evidence of disease induction. Initially, we confirmed the presence of CNS mast cells in naive animals used in this model system. Using metachromatic staining, mast cells were identified in CNS samples of wild-type mice only, particularly in perivascular regions of the hippocampus, leptomeninges, habenula, and thalamus (Fig. 2, A and B). Tissue samples from immunized wild-type and W/W^v^ mice were also examined for the presence of inflammatory lesions. Typical mononuclear infiltrates with perivascular cuffing were noted in the brains and spinal cords of diseased mice in both groups (Fig. 2, C and D). No apparent differences between the two groups were observed in the composition or distribution of inflammatory infiltrates. Mast cells were not identified in the inflammatory lesions of wild-type mice, consistent with the previous findings of Ibrahim et al. (35) in which mast cells were found in lesions from chronic but not acute disease.

Reconstitution of W/W^v^ Mice with BM MCs Restores EAE Disease Onset and Severity to Wild-Type Levels. If mast cell deficiency alone accounts for the differences in EAE disease parameters observed in W/W^v^ mice, reconstitution of the mast cell population in these animals should restore disease incidence and severity to the level of wild-type animals. The development of functional mast cells is dependent on the interaction of stem cell factor (SCF) with its receptor, c-kit, expressed on bone marrow–derived pluripotent stem cells. The mast cell deficiency of W/W^v^ mice is due to mutations in c-kit that compromise its signaling function (36, 37). The mast cell population can be reconstituted in these animals by intravenous injection of c-kit^+^ bone marrow cells or in vitro–differentiated, bone marrow–derived mast cell precursors (BM MCs) from wild-type animals (4, 27, 29, 38–43). Mast cell numbers in the skin, respiratory tract, and gastrointestinal tissues of the W/W^v^ mice after transplantation with either bone marrow cells or BM MCs are comparable to those of wild-type animals by 10–12 wk after transplantation. Importantly, the phenotypic characteristics of these cells resemble the local, native populations of mast cells in normal mice (29, 38, 39).

We performed mast cell reconstitution in 8–10-wk-old W/W^v^ recipients by intravenous injection of BM MCs (>96% purity, as determined by flow cytometry; Fig. 3) to

![Figure 1. W/W^v^ mice show a delay in disease onset and a reduction in disease severity. (A) Clinical scores were assigned daily to wild-type (n = 16) and W/W^v^ (n = 17) mice, and the mean of each group was reported (P < 0.0001 as determined by paired t test). (B) Graph represents the percent of total animals that demonstrated disease by day 30 after immunization (P < 0.0003). Curve was plotted according to the method of Kaplan-Meier, and significance was calculated by the log-rank test. Results in A and B represent cumulative data from three independent experiments.](image)

**Table I.** Cumulative Analysis of EAE Disease Parameters

<table>
<thead>
<tr>
<th>Group</th>
<th>Incidence*</th>
<th>Mean day of onset‡</th>
<th>Mean high score‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>P &lt; 0.003</td>
<td>P &lt; 0.03</td>
</tr>
<tr>
<td>Wild-type F1^+/+</td>
<td>15/16</td>
<td>18.0 ± 2.65</td>
<td>2.42 ± 0.28</td>
</tr>
<tr>
<td>W/W^v^</td>
<td>7/17</td>
<td>24.3 ± 2.96</td>
<td>0.61 ± 0.22</td>
</tr>
</tbody>
</table>

*Comparison of group incidence analyzed by Fisher's exact test.
‡Results are expressed as the mean (±SE). Comparisons analyzed by Student's t test.
§Only animals positive for disease are included in calculation.
repair the mast cell deficit. To assess the establishment of mast cells in these mice, animals were killed 14–16 wk after reconstitution, and major organs were examined for the presence and distribution of mast cells. Mast cells were observed in the gut, CNS, and bone marrow as well as other organs in distribution patterns consistent with those seen in wild-type mice (Fig. 4). As expected, no mast cells were detected in tissues obtained from W/Wv mice.

The selectivity of the mast cell reconstitution was confirmed by hematocrit (Hct) determination (27, 39–41). W/Wv mice are anemic (Hct 38.0 ± 3.0%) compared with wild-type F11/F11 mice (Hct 51.5 ± 0.71%). Reconstituted W/Wv mice remain anemic (Hct 33.6 ± 3.1%) after BMMC transplantation, demonstrating that all hematologic deficits are not restored by this procedure.

10 wk after reconstitution, BMMC recipients as well as age-matched wild-type and W/Wv mice were subjected to the EAE disease induction protocol. As shown in Fig. 5 A, re-establishment of the mast cell population in W/Wv mice completely restored the ability of these animals to develop severe disease. When compared with wild-type mice, the mast cell-reconstituted animals showed a similar time of onset, daily

Figure 2. Histologic analyses of CNS tissues in WBB6/F11/F11 mice. After sacrifice of the animals, brains, spinal columns, and other organs were removed and preserved in 10% neutral buffered formalin. Paraffin-embedded tissue sections were stained with Giemsa (A and B) or hematoxylin and eosin (C and D). (A) Mast cell (arrow) located within the thalamic border region of the habenula; ×40. (B) Two mast cells (arrows) located in the habenula. The third ventricle is also noted (V); ×20. Inset, the same two mast cells; ×40. (C) Multiple inflammatory infiltrates (arrows) found in spinal cord section of a diseased animal; ×10. (D) Focal inflammatory infiltrate found in the brain parenchyma of a diseased animal; ×40.

Figure 3. Flow cytometric analysis of the in vitro-differentiated BMMC population. Cells double positive for c-kit and FceRI were considered mast cells. Greater than 96% of the population was positive for both mast cell markers, c-kit (c-kit–PE) and FceRI (IgE + rat anti-mouse-FITC).
mean clinical score, and disease incidence (Fig. 5). Inflammatory infiltrates in the brain and spinal cord were also similar (data not shown). In all disease parameters examined, significant differences existed between mast cell–deficient mice and those with intact mast cell compartments (Fig. 5 and Table II).

In the reconstitution experiments, it was noted that wild-type and W/Wv animals demonstrated higher mean clinical scores than those observed in younger animals of respective genotypes (Fig. 1 A). In addition, some individual W/Wv mice had clinical scores as high as those of the wild-type animals. The explanation for these observations is unclear, but they may be due to age-related differences in host sensitivity to pertussis toxin or peptide dose. These possibilities are presently being examined.

Immunized W/Wv mice mount an M O G-specific T and B cell responses similar to wild-type F 1 /F 1 mice. While it is formally possible that W/Wv mice have T cell deficits that could account for the differences in disease parameters demonstrated between wild-type and mast cell–deficient animals, we believe this is unlikely. Thymocytes are c-kit+, and the defect in c-kit carried by W/Wv mice could potentially hinder T cell development in these animals; however, previous characterizations of W/Wv mice revealed no such T cell deficits (44, 45). It has also been demonstrated that IL-7, which has many activities that overlap with SCF, can direct the development of normal T cells in c-kit–deficient mice (44). In addition, we evaluated M O G-specific proliferative responses, cytokine profiles, and antibody production in both groups. Splenocytes from M O G-immunized wild-type and W/Wv mice mounted equivalent proliferative responses and IFN-γ cytokine production in response to in vitro stimulation with M O G peptide (data not shown). No IL-4 was detected in these assays. Wild-type and W/Wv mice, as well as BM-M C-reconstituted W/Wv animals, produced similar levels of M O G-specific IgG (Fig. 6). M O G-specific IgG1 and IgG2b subtypes were also detected in all three groups. Interestingly, the M O G-specific IgG1 levels of W/Wv and BM-M C-reconstituted W/Wv mice were significantly higher (P < 0.05, ANOVA) than
those of wild-type mice. The biological significance of this observation is unclear. However, it may indicate that c-kit signaling pathways play an as yet unidentified role in B cell isotype switching. Alternatively, the kinetics of IgG1 antibody production may be altered in these mutant animals. Despite these differences in IgG1 levels, it is unlikely that this has a major effect on the development of EAE, because wild-type and BMMC-reconstituted mice exhibit similar disease courses. Also of note, total serum IgE was high in immunized animals within all groups, yet MOG-specific IgE was undetectable (data not shown). These results indicate that there are no global T or B cell deficits in W/Wv mice. Taken together with the demonstration that mast cell reconstitution with a virtually pure BMMC population restores disease susceptibility, these data support the hypothesis that it is the absence of mast cells in the W/Wv animals that predisposes them to delayed onset and less severe disease.

**Discussion**

The data reported in this study provide direct evidence that mast cells influence both the initiation and the severity of EAE in vivo, yet many questions regarding mast cell activation and effector mechanisms remain to be answered. Although cross-linkage of the high-affinity IgE receptor (FcεRI) on mast cells is a well characterized pathway of mast cell activation, there are several alternative pathways that could be operational in this disease. Ig-dependent mechanisms may include involvement of anti-MOG antibodies, which have been implicated in both human and rodent forms of the disease (34, 46). Levels of IgG2b in particular are correlated with disease severity in MOG-induced EAE in NOD mice (47). Our finding that both IgG1 and IgG2b are produced in MOG-induced EAE, coupled with the fact that mast cells express FcγRIIB/III (receptors that specifically interact with these Ig subtypes; reference 48), is consistent with the possibility that these antibodies have a role in FcγR-mediated mast cell activation.

Mast cells can also be directly activated via Ig-independent pathways by neuropeptides, such as substance P, certain complement components, and estradiol, an observation that may explain the increased susceptibility of females to MS (49, 50). It was recently shown that activated T lymphocytes can induce degranulation and cytokine production by human mast cells after cell–cell contact (51, 52). These data indicate that direct interaction with autoreactive T cells may be sufficient for mast cell activation.

The site of mast cell activation and influence in this model of EAE is also unknown. We did not detect mast cells in the CNS lesions from wild-type or mast cell-reconstituted W/Wv mice. This may be due to the difficulty of detecting degranulated mast cells using classic histologic stains. Because of the potent activity of mast cell mediators, very few mast cells may be required to exert profound local effects. Alternatively, mast cells may act at sites distant from the site of CNS destruction. Activated mast cells can migrate to local lymph nodes (53), indicating their potential to influence naïve T cell activation and differentiation. Once mast cell activation occurs, the release of numerous mast cell mediators could act at several levels to influence disease induction and/or progression. For example, alteration of the blood–brain barrier through release of vasoactive amines may facilitate entry of autoreactive T cells into the CNS (54–56). Proinflammatory cytokines such as

**Table II.** Cumulative Analysis of EAE Disease Parameters in BMMC Reconstitution Experiments

<table>
<thead>
<tr>
<th>Group</th>
<th>Incidence*</th>
<th>Mean day of onset‡</th>
<th>Mean high score‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type F1&lt;sup&gt;+/+&lt;/sup&gt;</td>
<td>10/10</td>
<td>12.4 ± 0.64*</td>
<td>3.45 ± 0.31*</td>
</tr>
<tr>
<td>W/Wv</td>
<td>4/8</td>
<td>18.0 ± 2.64</td>
<td>1.63 ± 0.65</td>
</tr>
<tr>
<td>W/Wv + BMMC</td>
<td>12/12</td>
<td>13.1 ± 0.67&lt;sup&gt;i&lt;/sup&gt;</td>
<td>3.75 ± 0.17&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*Comparison of group incidence analyzed by Fisher’s exact test.
‡Results are expressed as the mean (±SE).
§Only animals positive for disease are included in calculation.
*iP < 0.05 or ¶P < 0.01 comparing wild-type or reconstituted group versus W/Wv as determined by Bonferroni ANOVA post-test analyses.

![Figure 6. Detection of MOG-specific IgG and IgG subclasses.](image-url)

Upon sacrifice, serum was obtained from wild-type (n = 16), W/Wv (n = 16), and BMMC-reconstituted W/Wv (n = 10) mice and analyzed for MOG-specific IgG1 and IgG subclasses by ELISA. Results represent cumulative data from four experiments.
TNF-α could regulate endothelial expression of adhesion molecules, kill myelin-producing cells, and degrade myelin components (57, 58). TNF-α has also been shown to promote local presentation of autoantigens in the diabetic model of NOD mice (59). Mast cell proteases may directly damage the myelin sheath and adjacent nerves (19, 21, 22). Finally, regulatory cytokines such as IL-4 and IL-10 could influence the development of an autoimmune T cell response or modulate an ongoing response both in the periphery and within the CNS (60, 61).

Until recently, the contribution of mast cells to nonspecific and specific inflammatory processes was virtually ignored outside the realm of allergy research. It is becoming increasingly clear that mast cells can provide protection in bacterial infections (27, 42). Through their ability to regulate a myriad of both adaptive and innate immune responses, mast cells may play a major role in many immune-mediated diseases as well. The demonstration that mast cells are significant effector cells in EAE alters the way we have classically thought about this disease in humans. These data pave the way for completely new avenues of immunotherapy that could complement treatment regimens based solely on altering the autoreactive T cell response.

We thank J.A. Kapp, S.W. Caughman, B.D. Evavold, R.D. Lopez, and A.E. Lukacher for helpful discussions, J. Holden for assistance with histological analyses, and A.W. Higbtower for assistance with statistical analyses.

This work was supported in part by the National Multiple Sclerosis Society. M.A. Brown was supported by a scholarship from the Leukemia Society of America.

Submitted: 28 September 1999
Revised: 6 January 2000
Accepted: 10 January 2000
Released online: 6 March 2000

References


